Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers
Christian Irsara, Alexander Egger, Wolfgang Prokop, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2021) Vol. 59, Iss. 8, pp. 1453-1462
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients
José Jesús Broseta, Diana Rodríguez‐Espinosa, Néstor Rodríguez, et al.
American Journal of Kidney Diseases (2021) Vol. 78, Iss. 4, pp. 571-581
Open Access | Times Cited: 112
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel
Avishay Spitzer, Yoel Angel, Or Marudi, et al.
JAMA (2022) Vol. 327, Iss. 4, pp. 341-341
Open Access | Times Cited: 94
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
Marc Peeters, Lise Verbruggen, Laure-Anne Teuwen, et al.
ESMO Open (2021) Vol. 6, Iss. 5, pp. 100274-100274
Open Access | Times Cited: 90
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study
Manoj Murhekar, Tarun Bhatnagar, Jeromie Wesley Vivian Thangaraj, et al.
PLoS Medicine (2021) Vol. 18, Iss. 12, pp. e1003877-e1003877
Open Access | Times Cited: 75
Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial
Simon Jochum, Imke Kirste, Sayuri Hortsch, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 49
COVID‐19 and plasma cells: Is there long‐lived protection?*
Doan C. Nguyen, Pedro A. Lamothe, Matthew C. Woodruff, et al.
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 40-63
Open Access | Times Cited: 41
Intensidad y duración de la respuesta inmune humoral a la vacuna para COVID 19 en trabajadores de la salud, utilizando una prueba de anticuerpos IgG cuantitativos
Gabriela Becerra, Sigifredo Ospina, Lisseth Pizano, et al.
Infectio (2025), pp. 16-22
Open Access
Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients
Yana Debie, Irene Garcia-Fogeda, Lander Willem, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test
Yoonjoo Kim, Ji Hyun Lee, Geon Young Ko, et al.
Diagnostics (2021) Vol. 11, Iss. 8, pp. 1496-1496
Open Access | Times Cited: 38
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study
Gábor J. Szebeni, Nikolett Gémes, Dániel Honfi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 25
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay
Minjeong Nam, Jong Do Seo, Hee‐Won Moon, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 3
Open Access | Times Cited: 29
Evaluation of Commercial Anti-SARS-CoV-2 Antibody Assays and Comparison of Standardized Titers in Vaccinated Health Care Workers
Kahina Saker, Vanessa Escuret, Virginie Pitiot, et al.
Journal of Clinical Microbiology (2021) Vol. 60, Iss. 1
Open Access | Times Cited: 28
The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study
Thomas Perkmann, Patrick Mucher, Nicole Perkmann‐Nagele, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 21
Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients
Diana Rodríguez‐Espinosa, Enrique Montagud‐Marrahí, Judit Cacho, et al.
Journal of Nephrology (2022) Vol. 35, Iss. 3, pp. 769-778
Open Access | Times Cited: 20
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
Jorge A. Soto, Felipe Melo-González, Cristián Gutiérrez-Vera, et al.
mBio (2022) Vol. 13, Iss. 6
Open Access | Times Cited: 20
Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France
Jean-François Verdier, S. Boyer, Florence Chalmin, et al.
BMC Nephrology (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer
Yana Debie, Jonas R.M. Van Audenaerde, Timon Vandamme, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 3, pp. 635-646
Open Access | Times Cited: 13
Heterologous Vector—mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector—Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines
Catharina Gerhards, Margot Thiaucourt, Michael Hetjens, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 701-701
Open Access | Times Cited: 7
A Systematic Review and Meta-Analysis Comparing the Diagnostic Accuracy Tests of COVID-19
Juan Jeferson Vilca-Alosilla, Mayron Antonio Candia-Puma, Katiusca Coronel-Monje, et al.
Diagnostics (2023) Vol. 13, Iss. 9, pp. 1549-1549
Open Access | Times Cited: 6
Anti-spike protein to determine SARS-CoV-2 antibody levels: Is there a specific threshold conferring protection in immunocompromised patients?
Philippe Halfon, Sylvie Jordana, Stéphane Blachier, et al.
PLoS ONE (2023) Vol. 18, Iss. 4, pp. e0281257-e0281257
Open Access | Times Cited: 5
Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
Mina Psichοgiou, Andreas Karabinis, Garyphallia Poulakou, et al.
Vaccines (2021) Vol. 9, Iss. 9, pp. 1017-1017
Open Access | Times Cited: 13
One-Year Follow-Up of COVID-19 Patients Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2 Antibodies
Alexander Egger, Sabina Sahanic, Andreas Gleiß, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 9
Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
Timna Agur, Naomi Ben-Dor, Michal Herman‐Edelstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis
Caroline M. Hsu, Eduardo Lacson, Harold J. Manley, et al.
American Journal of Kidney Diseases (2022) Vol. 80, Iss. 1, pp. 151-153
Open Access | Times Cited: 8
Antibody and T‐cell responses by ultra‐deep T‐cell receptor immunosequencing after COVID‐19 vaccination in patients with plasma cell dyscrasias
Alfred Chung, Barbara L. Banbury, Marissa Vignali, et al.
British Journal of Haematology (2022) Vol. 199, Iss. 4, pp. 520-528
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top